AIA
REGN icon

Affinity Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Affinity Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-608
Closed -$425K – 209
2022
Q1 		$425K Buy
608
+66
+12% +$41.8K 0.17% 151
2021
Q4 		$342K Buy
+542
New +$333K 0.14% 153

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Affinity Investment Advisors's REGN Position: Q2 2022 in Review

Affinity Investment Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 608 shares — an estimated $425K sold.

Affinity Investment Advisors first reported a position in REGN in Q4 2021 and held it in 2 quarters. The position peaked at $425K in Q1 2022. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

  • Affinity Investment Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Affinity Investment Advisors sold 608 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $425K.
  • Affinity Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Affinity Investment Advisors's Regeneron Pharmaceuticals position peaked at $425K in Q1 2022.
  • 1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Affinity Investment Advisors's 13F filing for Q2 2022, filed 27 Jul 2022.